You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameCandoxatril
Accession NumberDB00616  (APRD00027)
TypeSmall Molecule
GroupsExperimental
DescriptionCandoxatril is the orally-active prodrug of candoxatrilat (UK-73967), a potent neutral endopeptidase (NEP) inhibitor.
Structure
Thumb
Synonyms
[4(S)-cis]-4-[[[1-[3-[(2,3-dihydro-1H-Indeb5-yl)oxy]-2-[(2-methoxyethoxy)methyl]-3-oxopropyl]cyclopentyl]carbonyl]amino]cyclohexanecarboxylic acid
4-({1-[(S)-2-(indan-5-yloxycarbonyl)-3-(2-methoxy-ethoxy)-propyl]-cyclopentanecarbonyl}-amino)-cyclohexanecarboxylic acid
External Identifiers
  • UK-79,300
  • UK-79300
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIACP75508EE
CAS number123122-55-4
WeightAverage: 515.6383
Monoisotopic: 515.288302671
Chemical FormulaC29H41NO7
InChI KeyZTWZVMIYIIVABD-OEMFJLHTSA-N
InChI
InChI=1S/C29H41NO7/c1-35-15-16-36-19-23(27(33)37-25-12-9-20-5-4-6-22(20)17-25)18-29(13-2-3-14-29)28(34)30-24-10-7-21(8-11-24)26(31)32/h9,12,17,21,23-24H,2-8,10-11,13-16,18-19H2,1H3,(H,30,34)(H,31,32)/t21-,23-,24+/m0/s1
IUPAC Name
(1s,4s)-4-{1-[(2S)-3-(2,3-dihydro-1H-inden-5-yloxy)-2-[(2-methoxyethoxy)methyl]-3-oxopropyl]cyclopentaneamido}cyclohexane-1-carboxylic acid
SMILES
COCCOC[[email protected]](CC1(CCCC1)C(=O)N[[email protected]]1CC[[email protected]](CC1)C(O)=O)C(=O)OC1=CC2=C(CCC2)C=C1
Pharmacology
IndicationNot Available
Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of actionNeutral endopeptidase inhibitors such as Candoxatril have a dual mechanism of action. They inhibit two metalloprotease enzymes, neutral endopeptidase and ACE, resulting in an increased availability of natriuretic peptides that exhibit vasodilatory effects and, possibly, tissue protective effects.
TargetKindPharmacological actionActionsOrganismUniProt ID
NeprilysinProteinyes
inhibitor
HumanP08473 details
Angiotensin-converting enzymeProteinunknown
inhibitor
HumanP12821 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Candoxatril.Experimental
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with Candoxatril.Approved, Investigational
AcebutololCandoxatril may increase the hypotensive activities of Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Candoxatril is combined with Aceclofenac.Approved
AcetovanilloneThe risk or severity of adverse effects can be increased when Candoxatril is combined with Acetovanillone.Investigational
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Candoxatril.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Candoxatril is combined with Adapalene.Approved
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Candoxatril.Approved, Investigational
AliskirenAliskiren may increase the hyperkalemic activities of Candoxatril.Approved, Investigational
AllopurinolThe risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Candoxatril.Approved
AlogliptinThe risk or severity of adverse effects can be increased when Alogliptin is combined with Candoxatril.Approved
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Candoxatril.Approved, Illicit, Investigational
AlprenololCandoxatril may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AmbrisentanCandoxatril may increase the hypotensive activities of Ambrisentan.Approved, Investigational
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Candoxatril.Experimental
AmifostineCandoxatril may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideAmiloride may increase the hyperkalemic activities of Candoxatril.Approved
AmineptineThe serum concentration of Amineptine can be increased when it is combined with Candoxatril.Illicit, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Candoxatril.Approved
Aminosalicylic AcidAminosalicylic Acid may decrease the antihypertensive activities of Candoxatril.Approved
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Candoxatril.Approved
AmlodipineAmlodipine may increase the hypotensive activities of Candoxatril.Approved
AnisodamineThe risk or severity of adverse effects can be increased when Candoxatril is combined with Anisodamine.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Candoxatril is combined with Antipyrine.Approved
ApremilastThe risk or severity of adverse effects can be increased when Candoxatril is combined with Apremilast.Approved, Investigational
AprotininAprotinin may decrease the antihypertensive activities of Candoxatril.Approved, Withdrawn
ArdeparinArdeparin may increase the hyperkalemic activities of Candoxatril.Approved, Withdrawn
AtenololAtenolol may increase the hypotensive activities of Candoxatril.Approved
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Candoxatril.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Candoxatril is combined with Azapropazone.Withdrawn
AzathioprineCandoxatril may increase the myelosuppressive activities of Azathioprine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Candoxatril is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Candoxatril.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Candoxatril is combined with Balsalazide.Approved, Investigational
BemiparinBemiparin may increase the hyperkalemic activities of Candoxatril.Approved
BenazeprilBenazepril may increase the hypotensive activities of Candoxatril.Approved, Investigational
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Candoxatril.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Candoxatril.Withdrawn
BenoxaprofenThe risk or severity of adverse effects can be increased when Candoxatril is combined with Benoxaprofen.Withdrawn
BepridilCandoxatril may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetaxololBetaxolol may increase the hypotensive activities of Candoxatril.Approved
BethanidineBethanidine may increase the hypotensive activities of Candoxatril.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Candoxatril is combined with Betulinic Acid.Investigational
BimatoprostCandoxatril may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololBisoprolol may increase the hypotensive activities of Candoxatril.Approved
BoceprevirThe serum concentration of Candoxatril can be decreased when it is combined with Boceprevir.Approved
BosentanBosentan may increase the hypotensive activities of Candoxatril.Approved, Investigational
BretyliumCandoxatril may increase the hypotensive activities of Bretylium.Approved
BrimonidineBrimonidine may increase the hypotensive activities of Candoxatril.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Candoxatril.Approved
BromfenacThe risk or severity of adverse effects can be increased when Candoxatril is combined with Bromfenac.Approved
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Candoxatril.Approved, Investigational
BucillamineThe risk or severity of adverse effects can be increased when Candoxatril is combined with Bucillamine.Investigational
BumetanideBumetanide may increase the hypotensive activities of Candoxatril.Approved
BupranololCandoxatril may increase the hypotensive activities of Bupranolol.Approved
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Candoxatril.Approved
CanagliflozinCanagliflozin may increase the hyperkalemic activities of Candoxatril.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Candoxatril.Approved
CaptoprilCandoxatril may increase the hypotensive activities of Captopril.Approved
CarbamazepineThe metabolism of Candoxatril can be increased when combined with Carbamazepine.Approved, Investigational
CaroxazoneCaroxazone may increase the hypotensive activities of Candoxatril.Withdrawn
CarprofenThe risk or severity of adverse effects can be increased when Candoxatril is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololCarteolol may increase the hypotensive activities of Candoxatril.Approved
CarvedilolCandoxatril may increase the hypotensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Candoxatril is combined with Castanospermine.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Candoxatril is combined with Celecoxib.Approved, Investigational
CeliprololCandoxatril may increase the hypotensive activities of Celiprolol.Approved, Investigational
CertoparinCertoparin may increase the hyperkalemic activities of Candoxatril.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Candoxatril is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideCandoxatril may increase the hypotensive activities of Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Chlorotrianisene can be decreased when it is combined with Candoxatril.Withdrawn
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Candoxatril.Approved
CilazaprilCandoxatril may increase the hypotensive activities of Cilazapril.Approved
CiprofloxacinCandoxatril may increase the arrhythmogenic activities of Ciprofloxacin.Approved, Investigational
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Candoxatril.Approved, Investigational, Withdrawn
ClarithromycinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Candoxatril.Approved
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Candoxatril.Approved, Vet Approved
ClonidineClonidine may increase the hypotensive activities of Candoxatril.Approved
ClonixinThe risk or severity of adverse effects can be increased when Candoxatril is combined with Clonixin.Approved
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Candoxatril.Approved
CryptenamineCandoxatril may increase the hypotensive activities of Cryptenamine.Approved
CurcuminThe risk or severity of adverse effects can be increased when Candoxatril is combined with Curcumin.Investigational
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be increased when it is combined with Candoxatril.Approved
CyclophosphamideThe risk or severity of adverse effects can be increased when Candoxatril is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Candoxatril.Approved, Investigational, Vet Approved
CyclothiazideCyclothiazide may increase the hypotensive activities of Candoxatril.Approved
D-LimoneneThe risk or severity of adverse effects can be increased when Candoxatril is combined with D-Limonene.Investigational
DalteparinDalteparin may increase the hyperkalemic activities of Candoxatril.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Candoxatril.Investigational
DebrisoquinCandoxatril may increase the hypotensive activities of Debrisoquin.Approved
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Candoxatril.Approved
dersalazinedersalazine may decrease the antihypertensive activities of Candoxatril.Investigational
DeserpidineCandoxatril may increase the hypotensive activities of Deserpidine.Approved
DesipramineThe serum concentration of Desipramine can be increased when it is combined with Candoxatril.Approved
DiazoxideDiazoxide may increase the hypotensive activities of Candoxatril.Approved
DiclofenacThe risk or severity of adverse effects can be increased when Candoxatril is combined with Diclofenac.Approved, Vet Approved
DienestrolThe serum concentration of Dienestrol can be decreased when it is combined with Candoxatril.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Candoxatril.Approved
DiflunisalDiflunisal may decrease the antihypertensive activities of Candoxatril.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Candoxatril.Approved
DihydralazineCandoxatril may increase the hypotensive activities of Dihydralazine.Investigational
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Candoxatril.Approved
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Candoxatril.Approved
DorzolamideCandoxatril may increase the hypotensive activities of Dorzolamide.Approved
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Candoxatril.Approved
DoxazosinDoxazosin may increase the hypotensive activities of Candoxatril.Approved
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Candoxatril.Approved
DrospirenoneCandoxatril may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Candoxatril is combined with Droxicam.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Candoxatril is combined with Duvelisib.Investigational
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Candoxatril.Approved
E6201The risk or severity of adverse effects can be increased when Candoxatril is combined with E6201.Investigational
EbselenThe risk or severity of adverse effects can be increased when Candoxatril is combined with Ebselen.Investigational
EfonidipineCandoxatril may increase the hypotensive activities of Efonidipine.Approved
EnalaprilEnalapril may increase the hypotensive activities of Candoxatril.Approved, Vet Approved
EnalaprilatCandoxatril may increase the hypotensive activities of Enalaprilat.Approved
EnfuvirtideThe serum concentration of Enfuvirtide can be increased when it is combined with Candoxatril.Approved, Investigational
EnoxaparinEnoxaparin may increase the hyperkalemic activities of Candoxatril.Approved
EpirizoleThe risk or severity of adverse effects can be increased when Candoxatril is combined with Epirizole.Approved
EplerenoneEplerenone may increase the hyperkalemic activities of Candoxatril.Approved
EpoprostenolCandoxatril may increase the hypotensive activities of Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Candoxatril.Approved
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Candoxatril.Approved
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Candoxatril.Approved
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Candoxatril.Approved
EsmirtazapineThe serum concentration of Esmirtazapine can be increased when it is combined with Candoxatril.Investigational
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Candoxatril.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Estramustine can be decreased when it is combined with Candoxatril.Approved
Estrogens, esterifiedThe serum concentration of Estrogens, esterified can be decreased when it is combined with Candoxatril.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be decreased when it is combined with Candoxatril.Approved
Etacrynic acidEtacrynic acid may increase the hypotensive activities of Candoxatril.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Candoxatril is combined with Etanercept.Approved, Investigational
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Candoxatril.Approved
EtodolacThe risk or severity of adverse effects can be increased when Candoxatril is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Candoxatril is combined with Etofenamate.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Candoxatril is combined with Etoricoxib.Approved, Investigational
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Candoxatril.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Evening primrose oil.Approved
EverolimusThe risk or severity of adverse effects can be increased when Everolimus is combined with Candoxatril.Approved
exisulindThe risk or severity of adverse effects can be increased when Candoxatril is combined with exisulind.Investigational
FelodipineCandoxatril may increase the hypotensive activities of Felodipine.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Candoxatril is combined with Fenbufen.Approved
FenoldopamCandoxatril may increase the hypotensive activities of Fenoldopam.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Candoxatril is combined with Fenoprofen.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Candoxatril is combined with Floctafenine.Approved, Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Candoxatril is combined with Flunixin.Vet Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Candoxatril is combined with Flurbiprofen.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Candoxatril.Experimental
FosinoprilFosinopril may increase the hypotensive activities of Candoxatril.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Candoxatril.Approved, Vet Approved
FurosemideFurosemide may increase the hypotensive activities of Candoxatril.Approved, Vet Approved
GarlicThe serum concentration of Candoxatril can be decreased when it is combined with Garlic.Approved
GuanabenzCandoxatril may increase the hypotensive activities of Guanabenz.Approved
GuanadrelGuanadrel may increase the hypotensive activities of Candoxatril.Approved
GuanethidineCandoxatril may increase the hypotensive activities of Guanethidine.Approved
GuanfacineCandoxatril may increase the hypotensive activities of Guanfacine.Approved, Investigational
HeparinHeparin may increase the hyperkalemic activities of Candoxatril.Approved, Investigational
HexamethoniumCandoxatril may increase the hypotensive activities of Hexamethonium.Experimental
HexestrolThe serum concentration of Hexestrol can be decreased when it is combined with Candoxatril.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Candoxatril is combined with Higenamine.Investigational
HMPL-004The risk or severity of adverse effects can be increased when Candoxatril is combined with HMPL-004.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Candoxatril.Approved
HydralazineCandoxatril may increase the hypotensive activities of Hydralazine.Approved
HydrochlorothiazideCandoxatril may increase the hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideCandoxatril may increase the hypotensive activities of Hydroflumethiazide.Approved
IbuprofenThe risk or severity of adverse effects can be increased when Candoxatril is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Candoxatril is combined with Ibuproxam.Withdrawn
IcatibantIcatibant may decrease the antihypertensive activities of Candoxatril.Approved
IloprostIloprost may increase the hypotensive activities of Candoxatril.Approved, Investigational
ImidaprilCandoxatril may increase the hypotensive activities of Imidapril.Investigational
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Candoxatril.Approved
IndapamideCandoxatril may increase the hypotensive activities of Indapamide.Approved
IndenololCandoxatril may increase the hypotensive activities of Indenolol.Withdrawn
IndomethacinThe risk or severity of adverse effects can be increased when Candoxatril is combined with Indomethacin.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Candoxatril is combined with Indoprofen.Withdrawn
IndoraminCandoxatril may increase the hypotensive activities of Indoramin.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of Candoxatril.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Candoxatril.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Candoxatril.Approved, Investigational
IronThe risk or severity of adverse effects can be increased when Candoxatril is combined with Iron.Approved
Iron DextranThe risk or severity of adverse effects can be increased when Candoxatril is combined with Iron Dextran.Approved, Vet Approved
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Candoxatril.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Candoxatril is combined with Isoxicam.Withdrawn
IsradipineIsradipine may increase the hypotensive activities of Candoxatril.Approved
KebuzoneThe risk or severity of adverse effects can be increased when Candoxatril is combined with Kebuzone.Experimental
KetanserinCandoxatril may increase the hypotensive activities of Ketanserin.Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Candoxatril is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Candoxatril is combined with Ketorolac.Approved
LabetalolLabetalol may increase the hypotensive activities of Candoxatril.Approved
LacidipineCandoxatril may increase the hypotensive activities of Lacidipine.Approved
Lanthanum carbonateThe serum concentration of Candoxatril can be decreased when it is combined with Lanthanum carbonate.Approved
LatanoprostCandoxatril may increase the hypotensive activities of Latanoprost.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Candoxatril is combined with Leflunomide.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Candoxatril.Approved, Investigational
LinagliptinThe risk or severity of adverse effects can be increased when Linagliptin is combined with Candoxatril.Approved
LisinoprilCandoxatril may increase the hypotensive activities of Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Candoxatril is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Candoxatril.Approved
LofexidineCandoxatril may increase the hypotensive activities of Lofexidine.Approved, Investigational
LornoxicamThe risk or severity of adverse effects can be increased when Candoxatril is combined with Lornoxicam.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Candoxatril.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Candoxatril.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Candoxatril is combined with Loxoprofen.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Candoxatril is combined with Lumiracoxib.Approved, Investigational
MacitentanCandoxatril may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Candoxatril is combined with Magnesium salicylate.Approved
ManidipineCandoxatril may increase the hypotensive activities of Manidipine.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Candoxatril is combined with Masoprocol.Approved
MebanazineMebanazine may increase the hypotensive activities of Candoxatril.Withdrawn
MecamylamineCandoxatril may increase the hypotensive activities of Mecamylamine.Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Candoxatril is combined with Meclofenamic acid.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Candoxatril is combined with Mefenamic acid.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Candoxatril is combined with Meloxicam.Approved, Vet Approved
MesalazineMesalazine may decrease the antihypertensive activities of Candoxatril.Approved
MestranolThe serum concentration of Mestranol can be decreased when it is combined with Candoxatril.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Candoxatril is combined with Metamizole.Withdrawn
MethallenestrilThe serum concentration of Methallenestril can be decreased when it is combined with Candoxatril.Experimental
MethyclothiazideMethyclothiazide may increase the hypotensive activities of Candoxatril.Approved
MethyldopaCandoxatril may increase the hypotensive activities of Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Candoxatril.Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Candoxatril.Approved, Investigational
MetipranololCandoxatril may increase the hypotensive activities of Metipranolol.Approved
MetolazoneMetolazone may increase the hypotensive activities of Candoxatril.Approved
MetoprololMetoprolol may increase the hypotensive activities of Candoxatril.Approved, Investigational
MetyrosineCandoxatril may increase the hypotensive activities of Metyrosine.Approved
MibefradilCandoxatril may increase the hypotensive activities of Mibefradil.Withdrawn
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Candoxatril.Approved, Illicit
MinaprineMinaprine may increase the hypotensive activities of Candoxatril.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Candoxatril.Approved
MirtazapineThe serum concentration of Mirtazapine can be increased when it is combined with Candoxatril.Approved
MizoribineThe risk or severity of adverse effects can be increased when Candoxatril is combined with Mizoribine.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Candoxatril.Approved
MoexiprilCandoxatril may increase the hypotensive activities of Moexipril.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Candoxatril.Approved
MoxonidineCandoxatril may increase the hypotensive activities of Moxonidine.Approved
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Candoxatril is combined with Mycophenolic acid.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Candoxatril is combined with Nabumetone.Approved
NadololCandoxatril may increase the hypotensive activities of Nadolol.Approved
NadroparinNadroparin may increase the hyperkalemic activities of Candoxatril.Approved
NafamostatThe risk or severity of adverse effects can be increased when Candoxatril is combined with Nafamostat.Investigational
NaftifineThe risk or severity of adverse effects can be increased when Candoxatril is combined with Naftifine.Approved
NaftopidilCandoxatril may increase the hypotensive activities of Naftopidil.Investigational
NaproxenThe risk or severity of adverse effects can be increased when Candoxatril is combined with Naproxen.Approved, Vet Approved
NCX 4016The risk or severity of adverse effects can be increased when Candoxatril is combined with NCX 4016.Investigational
NebivololCandoxatril may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with Candoxatril.Approved, Withdrawn
NepafenacThe risk or severity of adverse effects can be increased when Candoxatril is combined with Nepafenac.Approved
NialamideNialamide may increase the hypotensive activities of Candoxatril.Withdrawn
NicardipineCandoxatril may increase the hypotensive activities of Nicardipine.Approved
NicorandilNicorandil may increase the hyperkalemic activities of Candoxatril.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Candoxatril is combined with Niflumic Acid.Approved
NiguldipineCandoxatril may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineCandoxatril may increase the hypotensive activities of Nilvadipine.Approved
NimesulideThe risk or severity of adverse effects can be increased when Candoxatril is combined with Nimesulide.Approved, Withdrawn
NimodipineNimodipine may increase the hypotensive activities of Candoxatril.Approved
NisoldipineNisoldipine may increase the hypotensive activities of Candoxatril.Approved
NitrendipineCandoxatril may increase the hypotensive activities of Nitrendipine.Approved
NitroaspirinNitroaspirin may decrease the antihypertensive activities of Candoxatril.Investigational
NitroprussideNitroprusside may increase the hypotensive activities of Candoxatril.Approved
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Candoxatril.Approved
ObinutuzumabCandoxatril may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Candoxatril.Withdrawn
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Candoxatril.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Candoxatril is combined with Olopatadine.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Candoxatril is combined with Olsalazine.Approved
OmapatrilatCandoxatril may increase the hypotensive activities of Omapatrilat.Investigational
OpipramolThe serum concentration of Opipramol can be increased when it is combined with Candoxatril.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Candoxatril is combined with Orgotein.Vet Approved
OxaprozinThe risk or severity of adverse effects can be increased when Candoxatril is combined with Oxaprozin.Approved
OxprenololCandoxatril may increase the hypotensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Candoxatril is combined with Oxyphenbutazone.Withdrawn
ParecoxibThe risk or severity of adverse effects can be increased when Candoxatril is combined with Parecoxib.Approved
PargylinePargyline may increase the hypotensive activities of Candoxatril.Approved
ParnaparinParnaparin may increase the hyperkalemic activities of Candoxatril.Approved
PenbutololCandoxatril may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentoliniumCandoxatril may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Candoxatril.Approved, Investigational
PerindoprilCandoxatril may increase the hypotensive activities of Perindopril.Approved
PethidineThe risk or severity of adverse effects can be increased when Candoxatril is combined with Pethidine.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Candoxatril.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Candoxatril.Withdrawn
PhenoxybenzamineCandoxatril may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Candoxatril.Withdrawn
PhentolamineCandoxatril may increase the hypotensive activities of Phentolamine.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Candoxatril is combined with Phenylbutazone.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Candoxatril is combined with Pimecrolimus.Approved, Investigational
PimozideThe serum concentration of Pimozide can be increased when it is combined with Candoxatril.Approved
PinacidilCandoxatril may increase the hypotensive activities of Pinacidil.Withdrawn
PindololCandoxatril may increase the hypotensive activities of Pindolol.Approved
PiretanidePiretanide may increase the hypotensive activities of Candoxatril.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Candoxatril is combined with Pirfenidone.Investigational
PirlindolePirlindole may increase the hypotensive activities of Candoxatril.Approved
PiroxicamThe risk or severity of adverse effects can be increased when Candoxatril is combined with Piroxicam.Approved, Investigational
PivhydrazinePivhydrazine may increase the hypotensive activities of Candoxatril.Withdrawn
PolythiazideCandoxatril may increase the hypotensive activities of Polythiazide.Approved
PrazosinPrazosin may increase the hypotensive activities of Candoxatril.Approved
PregabalinThe risk or severity of adverse effects can be increased when Candoxatril is combined with Pregabalin.Approved, Illicit, Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Candoxatril is combined with Propacetamol.Approved
PropranololPropranolol may increase the hypotensive activities of Candoxatril.Approved, Investigational
ProtriptylineThe serum concentration of Protriptyline can be increased when it is combined with Candoxatril.Approved
PTC299The risk or severity of adverse effects can be increased when Candoxatril is combined with PTC299.Investigational
QuinaprilCandoxatril may increase the hypotensive activities of Quinapril.Approved, Investigational
QuinethazoneQuinethazone may increase the hypotensive activities of Candoxatril.Approved
QuinineQuinine may increase the hypotensive activities of Candoxatril.Approved
RamiprilRamipril may increase the hypotensive activities of Candoxatril.Approved
RasagilineRasagiline may increase the hypotensive activities of Candoxatril.Approved
RemikirenRemikiren may increase the hypotensive activities of Candoxatril.Approved
RescinnamineCandoxatril may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Candoxatril.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Candoxatril is combined with Resveratrol.Experimental, Investigational
ReviparinReviparin may increase the hyperkalemic activities of Candoxatril.Approved
RilmenidineCandoxatril may increase the hypotensive activities of Rilmenidine.Investigational
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Candoxatril.Approved
RituximabCandoxatril may increase the hypotensive activities of Rituximab.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Candoxatril is combined with Rofecoxib.Investigational, Withdrawn
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Candoxatril.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Sacubitril.Approved
SafrazineSafrazine may increase the hypotensive activities of Candoxatril.Withdrawn
SalicylamideThe risk or severity of adverse effects can be increased when Candoxatril is combined with Salicylamide.Approved
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Candoxatril.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Candoxatril is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Candoxatril.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Candoxatril.Investigational
SaxagliptinThe risk or severity of adverse effects can be increased when Saxagliptin is combined with Candoxatril.Approved
SelegilineSelegiline may increase the hypotensive activities of Candoxatril.Approved, Investigational, Vet Approved
SelexipagCandoxatril may increase the hypotensive activities of Selexipag.Approved
SeratrodastThe risk or severity of adverse effects can be increased when Candoxatril is combined with Seratrodast.Approved, Investigational
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Candoxatril.Approved, Investigational
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Candoxatril.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Candoxatril.Approved
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Candoxatril.Approved, Investigational
SitagliptinThe risk or severity of adverse effects can be increased when Sitagliptin is combined with Candoxatril.Approved, Investigational
SitaxentanCandoxatril may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium aurothiomalateThe risk or severity of adverse effects can be increased when Candoxatril is combined with Sodium aurothiomalate.Approved
SpiraprilCandoxatril may increase the hypotensive activities of Spirapril.Approved
SpironolactoneSpironolactone may increase the hyperkalemic activities of Candoxatril.Approved
SRT501The risk or severity of adverse effects can be increased when Candoxatril is combined with SRT501.Investigational
St. John's WortThe metabolism of Candoxatril can be increased when combined with St. John's Wort.Nutraceutical
SulfasalazineThe risk or severity of adverse effects can be increased when Candoxatril is combined with Sulfasalazine.Approved
SulindacThe risk or severity of adverse effects can be increased when Candoxatril is combined with Sulindac.Approved
SuprofenThe risk or severity of adverse effects can be increased when Candoxatril is combined with Suprofen.Approved, Withdrawn
Synthetic Conjugated Estrogens, AThe serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Candoxatril.Approved
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Candoxatril.Approved, Investigational
TadalafilTadalafil may increase the antihypertensive activities of Candoxatril.Approved, Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Candoxatril.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Candoxatril.Approved, Investigational
TemocaprilCandoxatril may increase the hypotensive activities of Temocapril.Experimental, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Candoxatril is combined with Temsirolimus.Approved
TenoxicamThe risk or severity of adverse effects can be increased when Candoxatril is combined with Tenoxicam.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Candoxatril is combined with Tepoxalin.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Candoxatril is combined with Teriflunomide.Approved
TerlipressinCandoxatril may increase the hypotensive activities of Terlipressin.Approved, Investigational
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Candoxatril.Approved
TianeptineThe serum concentration of Tianeptine can be increased when it is combined with Candoxatril.Approved
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Candoxatril is combined with Tiaprofenic acid.Approved
TiboloneCandoxatril may increase the hypotensive activities of Tibolone.Approved
TicrynafenCandoxatril may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololTimolol may increase the hypotensive activities of Candoxatril.Approved
TinoridineThe risk or severity of adverse effects can be increased when Candoxatril is combined with Tinoridine.Investigational
TinzaparinTinzaparin may increase the hyperkalemic activities of Candoxatril.Approved
TipranavirThe serum concentration of Candoxatril can be decreased when it is combined with Tipranavir.Approved, Investigational
TizanidineTizanidine may increase the hypotensive activities of Candoxatril.Approved
TolazolineCandoxatril may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Candoxatril is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Candoxatril is combined with Tolmetin.Approved
ToloxatoneToloxatone may increase the hypotensive activities of Candoxatril.Approved
TolvaptanTolvaptan may increase the hyperkalemic activities of Candoxatril.Approved
TorasemideTorasemide may increase the hypotensive activities of Candoxatril.Approved
TrandolaprilTrandolapril may increase the hypotensive activities of Candoxatril.Approved
TranilastThe risk or severity of adverse effects can be increased when Candoxatril is combined with Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Candoxatril.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Candoxatril.Approved
TravoprostTravoprost may increase the hypotensive activities of Candoxatril.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Candoxatril.Approved, Investigational
TriamtereneTriamterene may increase the hyperkalemic activities of Candoxatril.Approved
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Candoxatril.Approved
TrichlormethiazideCandoxatril may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrimazosinCandoxatril may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanCandoxatril may increase the hypotensive activities of Trimethaphan.Approved
TrimethoprimTrimethoprim may increase the hyperkalemic activities of Candoxatril.Approved, Vet Approved
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Candoxatril.Approved
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Candoxatril is combined with Trisalicylate-choline.Approved
UdenafilUdenafil may increase the antihypertensive activities of Candoxatril.Approved, Investigational
UnoprostoneCandoxatril may increase the hypotensive activities of Unoprostone.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Candoxatril is combined with Valdecoxib.Investigational, Withdrawn
Valproic AcidThe serum concentration of Valproic Acid can be decreased when it is combined with Candoxatril.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Candoxatril.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Candoxatril.Approved
VerapamilThe metabolism of Verapamil can be decreased when combined with Candoxatril.Approved
VildagliptinThe risk or severity of adverse effects can be increased when Vildagliptin is combined with Candoxatril.Approved, Investigational
VinpocetineCandoxatril may increase the hypotensive activities of Vinpocetine.Investigational
XylometazolineCandoxatril may increase the hypotensive activities of Xylometazoline.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Candoxatril.Approved, Vet Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Candoxatril is combined with Zaltoprofen.Approved
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Candoxatril.Approved
ZileutonThe risk or severity of adverse effects can be increased when Candoxatril is combined with Zileuton.Approved, Investigational, Withdrawn
ZomepiracThe risk or severity of adverse effects can be increased when Candoxatril is combined with Zomepirac.Withdrawn
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB Entries
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9142
Blood Brain Barrier+0.8437
Caco-2 permeable-0.6787
P-glycoprotein substrateSubstrate0.8158
P-glycoprotein inhibitor INon-inhibitor0.8213
P-glycoprotein inhibitor IINon-inhibitor0.9075
Renal organic cation transporterNon-inhibitor0.7707
CYP450 2C9 substrateNon-substrate0.7497
CYP450 2D6 substrateNon-substrate0.7492
CYP450 3A4 substrateSubstrate0.6952
CYP450 1A2 substrateNon-inhibitor0.7035
CYP450 2C9 inhibitorNon-inhibitor0.7548
CYP450 2D6 inhibitorNon-inhibitor0.8484
CYP450 2C19 inhibitorNon-inhibitor0.6641
CYP450 3A4 inhibitorNon-inhibitor0.9144
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8421
Ames testNon AMES toxic0.62
CarcinogenicityNon-carcinogens0.9494
BiodegradationNot ready biodegradable0.8614
Rat acute toxicity2.5001 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9833
hERG inhibition (predictor II)Non-inhibitor0.5652
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP3.7Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00225 mg/mLALOGPS
logP3.55ALOGPS
logP4.68ChemAxon
logS-5.4ALOGPS
pKa (Strongest Acidic)4.29ChemAxon
pKa (Strongest Basic)1.32ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area111.16 Å2ChemAxon
Rotatable Bond Count13ChemAxon
Refractivity138.16 m3·mol-1ChemAxon
Polarizability57.2 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as indanes. These are compounds containing an indane moiety, which consists of a cyclopentane fused to a benzene ring.
KingdomOrganic compounds
Super ClassBenzenoids
ClassIndanes
Sub ClassNot Available
Direct ParentIndanes
Alternative Parents
Substituents
  • Indane
  • Fatty acid ester
  • Cyclohexylamine
  • Fatty acyl
  • Fatty amide
  • Dicarboxylic acid or derivatives
  • Secondary carboxylic acid amide
  • Carboxylic acid ester
  • Carboxamide group
  • Ether
  • Dialkyl ether
  • Carboxylic acid
  • Carboxylic acid derivative
  • Carboxylic acid amide
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Aromatic homopolycyclic compound
Molecular FrameworkAromatic homopolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Thermolysin-like specificity, but is almost confined on acting on polypeptides of up to 30 amino acids (PubMed:15283675, PubMed:8168535). Biologically important in the destruction of opioid peptides such as Met- and Leu-enkephalins by cleavage of a Gly-Phe bond (PubMed:17101991). Able to cleave angiotensin-1, angiotensin-2 and angiotensin 1-9 (PubMed:15283675). Involved in the degradation of at...
Gene Name:
MME
Uniprot ID:
P08473
Molecular Weight:
85513.225 Da
References
  1. O'Connell JE, Jardine AG, Davidson G, Connell JM: Candoxatril, an orally active neutral endopeptidase inhibitor, raises plasma atrial natriuretic factor and is natriuretic in essential hypertension. J Hypertens. 1992 Mar;10(3):271-7. [PubMed:1315825 ]
  2. Elsner D, Muntze A, Kromer EP, Riegger GA: Effectiveness of endopeptidase inhibition (candoxatril) in congestive heart failure. Am J Cardiol. 1992 Aug 15;70(4):494-8. [PubMed:1386491 ]
  3. Plamboeck A, Holst JJ, Carr RD, Deacon CF: Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig. Diabetologia. 2005 Sep;48(9):1882-90. Epub 2005 Jul 16. [PubMed:16025254 ]
  4. Sansoe G, Aragno M, Mastrocola R, Cutrin JC, Silvano S, Mengozzi G, Smedile A, Rosina F, Danni O, Rizzetto M: Overexpression of kidney neutral endopeptidase (EC 3.4.24.11) and renal function in experimental cirrhosis. Am J Physiol Renal Physiol. 2006 Jun;290(6):F1337-43. Epub 2006 Jan 31. [PubMed:16449355 ]
  5. Hirata Y, Suzuki E, Hayakawa H, Matsuoka H, Sugimoto T, Kangawa K, Matsuo H: Mechanisms of the natriuretic effects of neutral endopeptidase inhibition in Dahl salt-sensitive and salt-resistant rats. J Cardiovasc Pharmacol. 1994 Feb;23(2):283-90. [PubMed:7511759 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Converts angiotensin I to angiotensin II by release of the terminal His-Leu, this results in an increase of the vasoconstrictor activity of angiotensin. Also able to inactivate bradykinin, a potent vasodilator. Has also a glycosidase activity which releases GPI-anchored proteins from the membrane by cleaving the mannose linkage in the GPI moiety.
Gene Name:
ACE
Uniprot ID:
P12821
Molecular Weight:
149713.675 Da
References
  1. Dumoulin MJ, Adam A, Rouleau JL, Lamontagne D: Comparison of a vasopeptidase inhibitor with neutral endopeptidase and angiotensin-converting enzyme inhibitors on bradykinin metabolism in the rat coronary bed. J Cardiovasc Pharmacol. 2001 Apr;37(4):359-66. [PubMed:11300648 ]
  2. Kostova E, Jovanoska E, Zafirov D, Jakovski K, Maleska V, Slaninka-Miceska M: Dual inhibition of angiotensin converting enzyme and neutral endopeptidase produces effective blood pressure control in spontaneously hypertensive rats. Bratisl Lek Listy. 2005;106(12):407-11. [PubMed:16642666 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on October 14, 2016 10:58